Pfizer’s axitinib has impressed in phase III trials assessing its efficacy as a second line treatment for renal cell carcinoma. …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

